ProPhase Labs (PRPH) stock took off on Tuesday after the consumer healthcare company announced a patent update. The U.S. Patent and Trademark Office has issued its approval for a patent that covers its biomarker-based systems and methods to assess progression risk in Barrett’s esophagus and esophageal adenocarcinoma. This is a type of cancer that develops in the glandular cells lining the esophagus.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ted Karkus, CEO of ProPhase Labs, said, “With this newly issued patent, we believe we are well positioned to accelerate commercialization and broaden clinical access to BE-Smart.” BE-Smart is the company’s molecular diagnostic, which has achieved a greater than 95% technical success rate in detecting its patented panel of biomarkers.
Investors will also note that ProPhase Labs will release its Q2 2025 earnings report tomorrow. Wall Street’s estimates are for earnings per share of -15 cents and revenue of $3.55 million. ProPhase Labs has historically missed estimates more times than it has surpassed them.
ProPhase Labs Stock Movement Today
ProPhase Labs stock was up 26.98% in pre-market trading on Tuesday, following a 9.77% drop yesterday. Traders will also note that the shares have fallen 62.93% year-to-date and 88.6% over the past 12 months. Today’s movement came with heavy trading, as some 61 million shares changed hands, compared to a three-month daily average of about 903,000 units.
Is ProPhase Labs Stock a Buy, Sell, or Hold?
Turning to Wall Street, analysts’ coverage of ProPhase Labs is lacking. Fortunately, TipRanks’ AI analyst Spark has it covered. Spark rates PRPH stock a Neutral (46) with a 50-cent price target, representing a potential 77.49% upside for the shares.
